PMID- 16633140
OWN - NLM
STAT- MEDLINE
DCOM- 20070404
LR  - 20220410
IS  - 0271-0749 (Print)
IS  - 0271-0749 (Linking)
VI  - 26
IP  - 2
DP  - 2006 Apr
TI  - Risperidone-related weight gain: genetic and nongenetic predictors.
PG  - 128-34
AB  - OBJECTIVE: A serious side effect of atypical antipsychotics is increased body 
      weight, which leads to further morbidity and nonadherence to medication. It has 
      been suggested that both genetic and nongenetic variables may influence 
      antipsychotics-related weight gain. This study aimed to simultaneously explore 
      the effects of multiple candidate genes and environment factors on body weight of 
      schizophrenia patients who received risperidone, a commonly used atypical 
      antipsychotic agent. METHODS: One hundred twenty-three ethnically Han Chinese 
      inpatients with acutely exacerbated schizophrenia were given risperidone 
      monotherapy for up to 42 days. Body weight and clinical manifestations were 
      assessed biweekly. Drug efficacy was measured by the Positive and Negative 
      Syndrome Scale (PANSS), and safety was evaluated by the Extrapyramidal Symptom 
      Rating Scale (ESRS) and the UKU Side Effect Rating Scale. We collected body 
      weight as the response value. Potential prognostic factors were baseline body 
      weight, age, sex, diagnosis subtypes, risperidone dosage, PANSS total scores, 
      treatment duration (weeks 0-6), and 15 genetic variants [across 10 candidate 
      genes: 5-HT1A, 5-HT2A, 5-HT2C, 5-HT6, D1, D2, D3, and alpha1-adrenergic 
      receptors, brain-derived neurotrophic factor (BDNF), and cytochrome P450 2D6 
      (CYP2D6)]. Because there were repeated assessments, multiple linear regression 
      with the generalized estimating equation (GEE) method was used to adjust the 
      within-subject dependence. RESULTS: Of 15 genetic polymorphisms examined, 5-HT2A 
      102-T/C, 5-HT2C -759-C/T, 5-HT6 267-C/T, BDNF 66-Val/Met, and CYP2D6 188-C/T 
      significantly influenced body weight, and so did baseline body weight, age, 
      gender, schizophrenia subtype, and treatment duration and efficacy. CONCLUSIONS: 
      These results suggest that numerous genetic and nongenetic factors affect 
      antipsychotics-related weight gain.
FAU - Lane, Hsien-Yuan
AU  - Lane HY
AD  - Department of Psychiatry and Institute of Medical Sciences, China Medical 
      University, Taichung, Taiwan. hylane@www.cmuh.org.tw
FAU - Liu, Yi-Ching
AU  - Liu YC
FAU - Huang, Chieh-Liang
AU  - Huang CL
FAU - Chang, Yue-Cune
AU  - Chang YC
FAU - Wu, Po-Lun
AU  - Wu PL
FAU - Lu, Chung-Ta
AU  - Lu CT
FAU - Chang, Wen-Ho
AU  - Chang WH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Receptor, Serotonin, 5-HT2A)
RN  - 0 (Receptor, Serotonin, 5-HT2C)
RN  - 0 (Receptors, Serotonin)
RN  - 0 (serotonin 6 receptor)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2D6)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Antipsychotic Agents/administration & dosage/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/genetics
MH  - China
MH  - Cytochrome P-450 CYP2D6/genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Genetic
MH  - Prospective Studies
MH  - Psychiatric Status Rating Scales
MH  - Receptor, Serotonin, 5-HT2A/genetics
MH  - Receptor, Serotonin, 5-HT2C/genetics
MH  - Receptors, Serotonin/genetics
MH  - Risperidone/administration & dosage/*therapeutic use
MH  - Schizophrenia/*drug therapy/genetics
MH  - Sex Factors
MH  - Weight Gain/*drug effects/genetics
EDAT- 2006/04/25 09:00
MHDA- 2007/04/05 09:00
CRDT- 2006/04/25 09:00
PHST- 2006/04/25 09:00 [pubmed]
PHST- 2007/04/05 09:00 [medline]
PHST- 2006/04/25 09:00 [entrez]
AID - 00004714-200604000-00004 [pii]
AID - 10.1097/01.jcp.0000203196.65710.2b [doi]
PST - ppublish
SO  - J Clin Psychopharmacol. 2006 Apr;26(2):128-34. doi: 
      10.1097/01.jcp.0000203196.65710.2b.